Brett Sheridan, M.D., F.A.C.S., Surgical Director of Heart Transplantation and Mechanical Circulatory Support

California Pacific CURRENTS: The online journal of CPMC Research Institute

Developing new approaches to the surgical treatment of high-risk, advanced heart failure patients

Research Overview

  • Dr. Sheridan is renowned for his expertise in surgical approaches to the treatment of cardiovascular diseases. At California Pacific Medical Center, he serves as the Chief of Cardiothoracic surgery as well as Surgical Director of Heart Transplantation and Mechanical Circulatory Support.
  • His clinical focus is the surgical treatment of high-risk and advanced heart failure patients requiring intervention.
  • This includes the review, selection and management of patients for reconstructive cardiac intervention, ventricular assist devices (durable or temporary) and/or heart transplantation.
  • Dr. Sheridan provides exceptional advanced cardiac surgical care. During his 14 years of education of cardiothoracic residents, he served as Co-principal investigator on a National Institutes of Health sponsored research grant to examine optimal strategies for treating the elderly following myocardial infarction.
  • He helps lead surgical teams in advanced heat failure therapeutic trials, bringing notable clinical advances in ventricular assist devices and heart transplantation to patients daily.

Training

Dr. Sheridan received his Biology degree with Honors from Stanford University, where he was introduced to cardiac surgery by working in the Shumway Cardiovascular Research Center. He earned his medical degree under the guidance of Dr. Michael DeBakey at the Baylor College of Medicine in Houston. Dr. Sheridan completed his training in General Surgery and Cardiothoracic and Transplant at the University of Colorado and accepted his first staff position at the University of North Carolina.


 

 

Publication Search

Publications

Van Tuyl JS, Hollis IB, Alburikan KA, Tran RH, Murray BP, Rodgers JE, Katz JN, Sheridan BC, Warfarin and Aspirin Versus Warfarin Alone for Prevention of Embolic Events in Patients with a HeartMate II Left Ventricular Assist Device. ASAIO J

Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Colombo PC, Walsh MN, Milano CA, Patel CB, Jorde UP, Pagani FD, Aaronson KD, Dean DA, McCants K, Itoh A, Ewald GA, Horstmanshof D, Long JW, Salerno C, MOMENTUM 3 Investigators., A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med

Maltais S, Kilic A, Nathan S, Keebler M, Emani S, Ransom J, Katz JN, Sheridan B, Brieke A, Egnaczyk G, Entwistle JW 3rd, Adamson R, Stulak J, Uriel N, O'Connell JB, Farrar DJ, Sundareswaran KS, Gregoric I, PREVENT Study Investigators., PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study. J Heart Lung Transplant

Sheridan BC, Invited commentary. Ann Thorac Surg

Dean D, Kallel F, Ewald GA, Tatooles A, Sheridan BC, Brewer RJ, Caldeira C, Farrar DJ, Akhter SA, SSI Registry Investigators., Reduction in driveline infection rates: Results from the HeartMate II Multicenter Driveline Silicone Skin Interface (SSI) Registry. J Heart Lung Transplant

VIEW ALL
Brett Sheridan, M.D., F.A.C.S., Surgical Director of Heart Transplantation and Mechanical Circulatory Support
Primary Research Interests
  • Surgical treatment of high-risk and advanced heart failure patients requiring intervention
  • Review, selection and management of patients for reconstructive cardiac intervention, ventricular assist devices (durable or temporary) and/or heart transplantation

Research News & Highlights

Dr. Sheridan is helping lead Sutter Health's participation in the Momentum 3 trial, a prospective, multi-center, unblinded randomized study comparing the HeartMate 3 LVAS to the HeartMate II® LVAS in advanced stage heart failure patients.